Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer.

Hochster, HS; Liu, H; Berim, LD; Spencer, KR; Gulhati, P; DiRubbo, M; Cohen, SD; Lee, P; Leitner, SP; Radovich, D; Misdary, C; Perez, C; Datta, S; Gonzalez, A; Saunders, T; Boland, PM

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (): 144

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索